December 7, 2011

Division of Dockets Management

Food and Drug Administration

5630 Fishers Lane

Room 1061, HFA-305

Rockville, MD 20852 

The National Association of Medical Education Companies (NAMEC), a non-profit organization comprised of health care educators and their companies, applauds the Food and Drug Administration in its efforts to create risk evaluation management strategies (REMS) that formally incorporate continuing education for the health professions. NAMEC has reviewed and extends its support to the FDA’s recently released Blueprint for Prescriber Education for the Long-Acting/Extended-Release Opioid Class-Wide REMS (Docket No. FDA-2011-D-0771).  FDA’s recognition of the challenges posed in balancing appropriate pain management with the potential for misuse or abuse of long-acting opioids is demonstrated through this significant action in improvement of patient care. 

Continue reading here: Blueprint for Prescriber Training Program final 10-25-11.pdf